Fruquintinib Development Beyond News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Fruquintinib Development Beyond. Real-time updates on events, politics, business and more.

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of

September 7, 2022

— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease...

New York United States Israel General Hong Kong France General South Korea

Source: globenewswire.com

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

August 23, 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

New York United States France General Hong Kong South Korea City Of

Source: apnews.com

HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global

December 6, 2021

— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary objective is to confirm overall...

United States Marek Kania Eli Lilly Fruquintinib Development Beyond International Corporation Drug Administration

Source: globenewswire.com

Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: HUTCHMED Completes Planned Enrollment of FRESCO-2

December 6, 2021

Investegate announcements from Hutchmed China Ltd, HUTCHMED Completes Planned Enrollment of FRESCO-2

United States South Korea Hong Kong Mark Lee Zhou Yi Atholl Tweedie Freddy Crossley

Source: investegate.co.uk

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation